Opdualag (nivolumab and relatlimab)

pCPA File Number: 22581
Negotiation Status:
Active Negotiation
Opdualag (nivolumab and relatlimab) is indicated for the treatment of adult and pediatric patients 12 years of age or older with unresectable or metastatic melanoma who have not received prior systemic therapy for unresectable or metastatic melanoma
Bristol Myers Squibb
CDA-AMC Project Number:
pCPA Engagement Letter Issued:
Negotiation Process Concluded:
Not Applicable